Pharmacology: p53 activator. Restores wild-type p53 signaling and depletes mutant p53 gain of function.

Induces mutant p53 protein degradation via MDM2 and ubiquitin-proteasome pathway.

Induces p73-dependent cell death in cancer cells without toxicity toward normal cells¹

 Inhibition of p53-MDM2 interaction remains a viable strategy for cancer therapeutic development^2,3

References:

1. S Zhang et al. Cancer Res. 2015 75:3842

2. M Ferraiuolo et al. Front Oncol. 2016 6:77

3. B Hong et al. Curr. Drug Targets 2014 15:80

Additional Information

Additional Information